MaxCyte, Inc. to Post Q1 2025 Earnings of ($0.14) Per Share, William Blair Forecasts (NASDAQ:MXCT)

MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Investment analysts at William Blair issued their Q1 2025 earnings per share estimates for MaxCyte in a research note issued on Wednesday, May 8th. William Blair analyst M. Larew anticipates that the company will earn ($0.14) per share for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for MaxCyte's current full-year earnings is ($0.53) per share. William Blair also issued estimates for MaxCyte's Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS and Q4 2025 earnings at ($0.13) EPS.

A number of other brokerages have also recently weighed in on MXCT. Stephens reaffirmed an "overweight" rating and set a $11.00 price target on shares of MaxCyte in a research report on Tuesday, April 23rd. BTIG Research reduced their price objective on MaxCyte from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, March 13th.

MaxCyte Trading Up 0.2 %

Shares of MaxCyte stock traded up $0.01 during trading hours on Friday, reaching $4.74. The stock had a trading volume of 358,493 shares, compared to its average volume of 638,227. MaxCyte has a 1 year low of $2.45 and a 1 year high of $5.55. The firm has a market capitalization of $495.54 million, a price-to-earnings ratio of -12.81 and a beta of 1.36. The firm has a 50 day simple moving average of $4.11 and a two-hundred day simple moving average of $4.38.

MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05. The company had revenue of $15.67 million for the quarter, compared to analyst estimates of $15.60 million. MaxCyte had a negative net margin of 91.85% and a negative return on equity of 15.90%.

Hedge Funds Weigh In On MaxCyte

A number of institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. increased its holdings in MaxCyte by 23.0% in the fourth quarter. Victory Capital Management Inc. now owns 12,316 shares of the company's stock valued at $58,000 after buying an additional 2,306 shares during the last quarter. M&T Bank Corp boosted its stake in MaxCyte by 3.4% in the third quarter. M&T Bank Corp now owns 163,513 shares of the company's stock valued at $510,000 after acquiring an additional 5,443 shares during the period. PNC Financial Services Group Inc. acquired a new position in shares of MaxCyte during the fourth quarter worth approximately $29,000. Russell Investments Group Ltd. acquired a new position in shares of MaxCyte during the first quarter worth approximately $28,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of MaxCyte by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company's stock worth $83,000 after buying an additional 7,898 shares during the period. 68.81% of the stock is owned by institutional investors and hedge funds.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.